SEC Form 4 · accession 0000899243-15-004436
Clovis Oncology, Inc. · CLVS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Erle T Mast
Officer — Executive VP and CFO
Period of report
Sep 1, 2015
Accepted (ET)
Sep 3, 2015 · 4:15 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001466301
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F5 | Sep 1, 2015 | S | 200 | $76.39 | D | 144,383 | D | |
| Common StockF2,F5 | Sep 1, 2015 | S | 400 | $78.2325 | D | 143,983 | D | |
| Common StockF3,F5 | Sep 1, 2015 | S | 1,000 | $79.394 | D | 142,983 | D | |
| Common StockF4,F5 | Sep 1, 2015 | S | 1,300 | $80.3431 | D | 141,683 | D | |
| Common StockF5 | Sep 1, 2015 | S | 100 | $81.07 | D | 141,583 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1This transaction was executed in multiple trades at prices ranging from $76.12 to $76.66. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F2This transaction was executed in multiple trades at prices ranging from $77.84 to $78.60. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F3This transaction was executed in multiple trades at prices ranging from $78.99 to $79.84. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F4This transaction was executed in multiple trades at prices ranging from $80.00 to $80.64. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F5The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2014.